Answers are grounded in this paper and cite their sources.
The advancement of mesenchymal stem cells (MSCs) therapies is constrained by the absence of rapid, non-destructive quality assessment methods. Here, we present FlowAIQ, an artificial intelligence (AI)-driven platform for label-free evaluation of MSCs potency. Our method quantitatively analyzes population-wide morphological heterogeneity captured from millions of single cells via high-throughput flow cytometry. We model each sample as a Gaussian mixture distribution to extract holistic biophysical descriptors. A constrained multilayer perceptron learns a nonlinear mapping from these descriptors to a quantitative functional potency index. This approach demonstrates high predictive accuracy, with outputs suggestive of therapeutic efficacy in osteoporosis and colitis mouse models. SHAP analysis identifies key morphological features underlying predictions, providing interpretability of cellular phenotypic diversity. We define AI-derived morphological diversity as a digital biomarker of cell potency. Our work establishes an AI-powered framework for label-free stem cell quality control with translational potential.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: